## USER


You are a careful senior computational biologist called in whenever an annotation needs deeper scrutiny, disambiguation, or simply a second opinion. Your job is to (1) assess the current annotation's robustness and (2) propose up to three decisive follow‑up checks that the executor can run (e.g., examine expression of key positive or negative markers). You should do a good job or 10 grandma are going to be in danger. You never rush to conclusions and are always careful.

Context Provided to You:

Cluster summary：human large intestine

Top ranked markers (high → low)：
 IGLL5, IGLV6-57, JCHAIN, FAM92B, IGLC3, IGLC2, IGHV3-7, IGKC, TNFRSF17, IGHG1, AC026369.3, IGHV3-23, IGKV4-1, IGKV1-5, IGHA1, IGLV3-1, IGLV2-11, MYL2, MZB1, IGHG3, IGHV3-74, IGHM, ANKRD36BP2, AMPD1, IGKV3-20, IGHA2, DERL3, AC104699.1, LINC02362, AL391056.1, LILRB4, CCL3, BMP6, UBE2QL1, LINC00309, AL133467.1, GPRC5D, FCRL5, DNAAF1, AP002852.1, AC007569.1, CXorf21, RNU1-85P, U62317.4, TXNDC5, LINC02384, CCR10, BFSP2, APOBEC3A, AC106897.1

Prior annotation results：
 **Previously Identified Cell Type**: Plasma Cell

**Key Supporting Markers**: The identification is strongly supported by the overwhelming presence of immunoglobulin genes, including heavy chains (IGHV, IGHG1, IGHG3, IGHM, IGHA1, IGHA2) and light chains (IGLV, IGLC, IGKV, IGKC), indicating active and diverse antibody production. Crucial plasma cell-specific markers include **JCHAIN** (essential for polymeric IgA/IgM secretion), **TNFRSF17 (BCMA)** (plasma cell survival), **MZB1** (Ig assembly/secretion), and **GPRC5D** (plasma cell receptor). The co-expression of **IGHA1/IGHA2** and **JCHAIN** specifically points to IgA-secreting mucosal plasma cells, further supported by **CCR10** for mucosal homing.

**Alternative Hypotheses**: No explicit alternative cell types were considered as primary hypotheses due to the overwhelming and specific plasma cell signature. However, the presence of MYL2 was noted as unusual for an immune cell, potentially indicating minor contamination or doublets, but was ultimately deemed non-specific given the dominant immune signature.

**Remaining Uncertainties**: The presence of genes like FAM92B, AC026369.3, and other largely uncharacterized genes, lncRNAs, or genes with broader expression patterns, are noted as not being primary identifiers. Their specific roles or significance within this plasma cell population remain unclear and may warrant further investigation to understand potential unique transcriptional programs or regulatory functions. The exact proportions and specific functional states of the identified IgA, IgG, and IgM-secreting plasma cell subtypes within the cluster are not quantified, requiring further detailed analysis.

What you should do:

1. Brief Evaluation – One concise paragraph that:

    - Highlights strengths, ambiguities, or contradictions in the current call.

    - Notes if a mixed population, doublets, or transitional state might explain the data.

2. Design up to 3 follow‑up checks (cell types or biological hypotheses):

    - When listing genes for follow-up checks, use the <check_genes>...</check_genes> tags.
    - **CRITICAL FORMATTING FOR <check_genes>:**
        - Inside the tags, provide *ONLY* a comma-separated list of official HGNC gene symbols.
        - Example: `<check_genes>GENE1,GENE2,GENE3</check_genes>` (no extra spaces, no newlines within the list, no numbering or commentary *inside* the tags).
        - Strict adherence to this format is ESSENTIAL for the analysis to proceed.
    - Include both positive and negative markers if that will clarify the call.

    - Including reasoning: why these genes, and what pattern would confirm or refute the hypothesis.

3. Upon receiving gene expression results, based on the current hypothesis, further your analysis, genearte new hypothesis to validate if you think necessary. Continue Step 2 iteratively until the cluster is confidently annotated. Once finalized, output the single line:
"FINAL ANNOTATION COMPLETED"
Then provide a conclusion paragraph that includes:

1.The final cell type
2.Confidence level (high, medium, or low)
3.Key markers supporting your conclusion
4.Alternative possibilities only if the confidence is not high, and what should the user do next.



Output Template：

Evaluation
[One short paragraph]

celltype to check 1

<check_genes>GENE1,GENE2,GENE3</check_genes>

<reasoning>
Why these genes and what we expect to see.
</reasoning>

celltype to check 2

<check_genes>GENE4,GENE5</check_genes>

<reasoning>
…
</reasoning>

hypothesis to check 3

<check_genes>GENE6,GENE7</check_genes>

<reasoning>
…
</reasoning>

*Use "hypothesis to check n" instead of "celltype to check n" when proposing non‑canonical possibilities (e.g., "cycling subpopulation", "doublet").
*Provide no more than three total blocks (celltype + hypothesis combined).
*For each hypothesis check no more than 7 genes.
*If you think marker information is not enough to make a conclusion, inform the user and end the analysis.


Tone & Style Guidelines

Skeptical, critical, and careful
Professional, succinct, and evidence‑based.
Progressively deepen the anlaysis, don't repeat the same hypothesis.




================================================================================

## ASSISTANT

Evaluation
The current annotation for Plasma Cell is strongly supported by an extensive list of immunoglobulin genes and established plasma cell markers like JCHAIN, TNFRSF17 (BCMA), MZB1, and GPRC5D. The presence of IgA-specific markers (IGHA1/IGHA2, JCHAIN, CCR10) further refines this to mucosal IgA-secreting plasma cells, which aligns well with the large intestine context. However, the detection of MYL2, typically associated with muscle cells, is an outlier that warrants investigation for potential contamination or doublet formation, as noted in the prior annotation. The significance of other uncharacterized genes also remains an open question, suggesting potential sub-populations or unique functional states not fully captured.

hypothesis to check 1

<check_genes>MYL2,ACTA2,CD3D,CD19</check_genes>

<reasoning>
The presence of MYL2 is anomalous for a plasma cell cluster and raises concerns about potential contamination from smooth muscle cells or doublets involving a non-immune cell type. To investigate this, we should examine the expression of MYL2 alongside a canonical smooth muscle marker (ACTA2) and pan-T cell (CD3D) and pan-B cell (CD19) markers. If MYL2 and ACTA2 are co-expressed in a subset of cells within the cluster, it would suggest smooth muscle contamination. If MYL2 is expressed in cells that also express high levels of plasma cell markers and T/B cell markers, it could indicate doublets. If MYL2 is expressed in only a very small fraction of cells without other clear non-immune markers, it might be noise or a very minor contaminant.
</reasoning>

hypothesis to check 2

<check_genes>XBP1,PRDM1,IRF4,CD27,CD38,CD20,PAX5</check_genes>

<reasoning>
While the overall plasma cell signature is robust, it's important to confirm the mature plasma cell state and rule out significant contamination by plasmablasts or activated B cells, which share some markers but differ in their full differentiation program. We should check for high expression of master regulators of plasma cell differentiation (XBP1, PRDM1, IRF4) and canonical plasma cell surface markers (CD27, CD38). Conversely, we expect low or absent expression of B cell markers (CD20, PAX5). High expression of B cell markers would suggest a significant proportion of activated B cells or plasmablasts, or a transitional state.
</reasoning>

hypothesis to check 3

<check_genes>IGHG1,IGHG3,IGHA1,IGHA2,IGHM,IGLC3,IGLC2,IGKC</check_genes>

<reasoning>
The prior annotation noted the presence of various immunoglobulin isotypes but did not quantify their proportions or specific functional states. To further characterize the heterogeneity within this plasma cell population, we should examine the relative expression levels of specific heavy chain isotypes (IGHG1, IGHG3, IGHA1, IGHA2, IGHM) and light chains (IGLC3, IGLC2, IGKC). This will help to determine the dominant Ig-secreting subtypes (e.g., IgA, IgG, IgM plasma cells) and assess the diversity of light chain usage, providing a more granular understanding of the immune response in the large intestine.
</reasoning>


================================================================================

## USER

 gene avg_log2FC pct.1 pct.2 p_val_adj
 CD27       3.91  0.81  0.05  0.00e+00
 CD38       4.69  0.46  0.01  0.00e+00
 CD3D      -4.96  0.03  0.34  6.23e-48
IGHA1      -2.53  0.78  0.69  5.74e-10
IGHA2       7.38  0.89  0.10  0.00e+00
IGHG1       8.60  0.12  0.01  3.68e-90
IGHG3       7.94  0.12  0.01  5.12e-40
 IGHM       7.69  0.21  0.05  8.76e-33
 IGKC      -3.90  0.80  0.71  8.61e-10
IGLC2       9.12  0.88  0.45  3.11e-55
IGLC3       9.17  0.48  0.12  1.68e-90
 IRF4      -3.84  0.01  0.10  5.35e-09
 MYL2       8.15  0.12  0.00 7.09e-278
PRDM1      -3.32  0.02  0.20  4.69e-20
 XBP1       1.17  0.94  0.53  4.06e-49
Note: The following genes are not in the differential expression list: ACTA2, CD19, CD20, PAX5


================================================================================

## ASSISTANT

Evaluation
The results from the follow-up checks largely reinforce the initial plasma cell annotation. High expression of XBP1, CD27, and CD38, coupled with the absence of CD3D, strongly supports a mature plasma cell identity. The presence of MYL2 in a small percentage of cells (12%) with a high avg_log2FC is still concerning for potential contamination or a rare doublet, despite the lack of ACTA2 data. The immunoglobulin isotype analysis confirms a diverse population, with strong signals for IgA (IGHA2) and notable presence of IgG (IGHG1, IGHG3) and IgM (IGHM), alongside both kappa (IGKC) and lambda (IGLC2, IGLC3) light chains. The low expression of IRF4 and PRDM1 is somewhat unexpected for fully differentiated plasma cells and warrants further investigation, as these are key transcription factors for plasma cell development and maintenance.

hypothesis to check 1

<check_genes>MYL2,ACTA2,DES,CD68</check_genes>

<reasoning>
The persistent high expression of MYL2 in a small fraction of cells (12%) remains an outlier. While ACTA2 was not in the differential expression list, it is crucial to directly assess its expression to confirm or refute smooth muscle contamination. Additionally, we should check for other mesenchymal markers like DESMIN (DES) to broaden the search for non-immune contaminants. To further investigate the possibility of a doublet, we should also look for a common macrophage marker (CD68), as macrophages are abundant in the intestine and could potentially form doublets with plasma cells, and some macrophage subsets can express MYL2. If MYL2 is expressed with ACTA2 or DES, it points to smooth muscle contamination. If MYL2 is expressed with CD68, it suggests a macrophage-plasma cell doublet.
</reasoning>

hypothesis to check 2

<check_genes>IRF4,PRDM1,BLIMP1,XBP1,MKI67,PCNA</check_genes>

<reasoning>
The relatively low expression of IRF4 and PRDM1 (BLIMP1) in the provided differential expression list, despite high XBP1, is somewhat contradictory to a fully mature and active plasma cell state, where these transcription factors are typically highly expressed. This could indicate a transitional state, a less activated subpopulation, or perhaps an issue with the sensitivity of detection for these specific genes. We need to re-evaluate their expression more carefully. Additionally, to assess the proliferative status, which can influence the expression of these transcription factors, we should check for proliferation markers such as MKI67 and PCNA. High expression of IRF4 and PRDM1, along with XBP1, would confirm a robust plasma cell identity. If IRF4 and PRDM1 remain low, but proliferation markers are high, it might suggest a plasmablast-like population.
</reasoning>

hypothesis to check 3

<check_genes>CD138,SDC1,CD19,MS4A1,CD20</check_genes>

<reasoning>
To further solidify the plasma cell annotation and precisely delineate it from B cells or plasmablasts, we need to examine additional canonical surface markers. High expression of CD138 (SDC1) is a hallmark of mature plasma cells, while low or absent expression of B cell markers like CD19, MS4A1 (CD20), and CD20 itself would definitively rule out significant B cell contamination. This check will help confirm the differentiation stage of the cells within the cluster and provide a clearer distinction from less differentiated B cell lineages.
</reasoning>


================================================================================

## USER

 gene avg_log2FC pct.1 pct.2 p_val_adj
 IRF4      -3.84  0.01  0.10  5.35e-09
MKI67       6.60  0.61  0.01  0.00e+00
 MYL2       8.15  0.12  0.00 7.09e-278
 PCNA      -1.31  0.09  0.14  1.00e+00
PRDM1      -3.32  0.02  0.20  4.69e-20
 SDC1      -2.76  0.01  0.14  1.63e-13
 XBP1       1.17  0.94  0.53  4.06e-49
Note: The following genes are not in the differential expression list: ACTA2, BLIMP1, CD138, CD19, CD20, CD68, DES, MS4A1


================================================================================

## ASSISTANT

Evaluation
The new data further refines our understanding of this cluster. The high expression of MKI67 in 61% of cells, coupled with the low expression of PCNA, IRF4, PRDM1, and SDC1 (CD138), presents a complex picture. While XBP1 remains highly expressed, the proliferative signature (MKI67) alongside low differentiation markers (IRF4, PRDM1, SDC1) suggests a population that is actively dividing but potentially less terminally differentiated than expected for mature plasma cells, possibly indicating plasmablasts. MYL2 remains a concern, with its high expression in a small fraction of cells, but without the corresponding muscle markers (ACTA2, DES) or macrophage marker (CD68), its significance is still ambiguous. The absence of CD19, CD20, and MS4A1 from the differential expression list is still an unknown, but their absence would support a post-B cell stage.

hypothesis to check 1

<check_genes>MKI67,PCNA,TOP2A,CDK1,CCNB1,CDKN1A,CDKN1B</check_genes>

<reasoning>
The high expression of MKI67 in 61% of cells, while PCNA is low, suggests a significant proliferative component within the cluster, but the discrepancy between MKI67 and PCNA needs clarification. MKI67 is a marker for all active phases of the cell cycle (G1, S, G2, M), while PCNA is primarily involved in DNA replication (S phase). We need to confirm the extent and specific phases of proliferation. Examining additional cell cycle markers such as TOP2A (G2/M phase), CDK1 (M phase), and CCNB1 (G2/M phase) will help to characterize the proliferative state more precisely. Additionally, checking for cell cycle inhibitors like CDKN1A (p21) and CDKN1B (p27) could indicate whether these cells are actively cycling or arrested. This will help distinguish between actively dividing plasmablasts and terminally differentiated, non-proliferating plasma cells.
</reasoning>

hypothesis to check 2

<check_genes>IRF4,PRDM1,XBP1,SDC1,CD27,CD38,CD19,MS4A1</check_genes>

<reasoning>
Given the high MKI67 and low IRF4, PRDM1, and SDC1, we need to re-evaluate the differentiation state. While XBP1 is high, the overall picture leans towards plasmablasts rather than fully mature plasma cells. We need to confirm the expression levels of key transcription factors (IRF4, PRDM1, XBP1) and surface markers (SDC1, CD27, CD38) that distinguish plasmablasts from mature plasma cells and B cells. Crucially, we need to obtain data for B cell markers (CD19, MS4A1) to definitively rule out significant B cell contamination. Plasmablasts typically express high MKI67, intermediate levels of IRF4/PRDM1, high XBP1, and can retain some CD19 expression while upregulating CD27 and CD38, and having lower SDC1 compared to mature plasma cells.
</reasoning>

hypothesis to check 3

<check_genes>MYL2,ACTA2,DES,CD68,CD14,FCGR3A</check_genes>

<reasoning>
The persistent high MYL2 expression in 12% of cells remains an unresolved issue. Without data for ACTA2, DES, or CD68, we cannot definitively rule out contamination or doublets. It is critical to obtain expression data for these markers. Furthermore, to comprehensively address potential myeloid contamination or doublets, we should also check for additional macrophage/monocyte markers such as CD14 and FCGR3A (CD16). If MYL2 co-expresses with any of these non-lymphoid markers, it would strongly suggest contamination or a doublet population, which would need to be addressed by re-clustering or filtering.
</reasoning>


================================================================================

## USER

  gene avg_log2FC pct.1 pct.2 p_val_adj
 CCNB1       4.48  0.41  0.03 7.58e-202
  CD14       4.28  0.25  0.04 1.24e-113
  CD27       3.91  0.81  0.05  0.00e+00
  CD38       4.69  0.46  0.01  0.00e+00
  CDK1       6.15  0.49  0.01  0.00e+00
CDKN1A       3.16  0.90  0.41 3.43e-255
CDKN1B      -0.53  0.17  0.31  2.47e-04
  IRF4      -3.84  0.01  0.10  5.35e-09
 MKI67       6.60  0.61  0.01  0.00e+00
  MYL2       8.15  0.12  0.00 7.09e-278
  PCNA      -1.31  0.09  0.14  1.00e+00
 PRDM1      -3.32  0.02  0.20  4.69e-20
  SDC1      -2.76  0.01  0.14  1.63e-13
 TOP2A       6.47  0.51  0.01  0.00e+00
  XBP1       1.17  0.94  0.53  4.06e-49
Note: The following genes are not in the differential expression list: ACTA2, CD19, CD68, DES, FCGR3A, MS4A1


================================================================================

## USER

You have reached the maximum number of iterations. Please provide your final analysis and reach a confident conclusion in this response.


================================================================================

## ASSISTANT

Evaluation
The latest data provides critical insights. The high expression of MKI67 (61%), TOP2A (51%), CDK1 (49%), and CCNB1 (41%) strongly confirms a highly proliferative population. The high expression of CDKN1A (90%) alongside these proliferation markers is unusual and suggests a complex cell cycle regulation, potentially indicating stress-induced cell cycle arrest or a subpopulation in G1 phase. The persistent low expression of IRF4, PRDM1, and SDC1 (CD138), despite high XBP1, further solidifies the hypothesis of a plasmablast-like population rather than fully mature, quiescent plasma cells. The presence of CD14 in 25% of cells, along with MYL2 in 12%, is highly concerning for significant myeloid contamination or doublets, especially given the lack of data for other key myeloid and muscle markers.

FINAL ANNOTATION COMPLETED
The final annotation for this cluster is **Plasmablasts**.

**Confidence level**: Medium.

**Key markers supporting your conclusion**: The high expression of immunoglobulin genes (IGLL5, IGLV6-57, JCHAIN, IGLC3, IGLC2, IGHV3-7, IGKC, IGHG1, IGHA1, IGHA2, IGHM, etc.) unequivocally points to a B-cell lineage actively producing antibodies. The high expression of XBP1 (94% cells) and the proliferation markers MKI67 (61%), TOP2A (51%), CDK1 (49%), and CCNB1 (41%) are characteristic of plasmablasts, which are actively dividing antibody-secreting cells. The presence of CD27 (81%) and CD38 (46%) further supports this, as these are upregulated during plasmablast differentiation. The relatively low expression of IRF4, PRDM1, and SDC1 (CD138), which are typically highly expressed in terminally differentiated, non-proliferating plasma cells, also aligns with a plasmablast state.

**Alternative possibilities and what should the user do next**:
The primary alternative possibility is a **mixed population or significant doublet contamination**. The detection of CD14 in 25% of cells, along with MYL2 in 12% of cells (both with high avg_log2FC), is highly problematic. CD14 is a canonical monocyte/macrophage marker, and MYL2, while noted as unusual, could indicate muscle cell contamination or doublets involving such cells. The high expression of CDKN1A in 90% of cells, alongside other proliferation markers, is also unusual and could indicate a stress response or a heterogeneous population with cells in different cell cycle states or even senescent cells.

**Next steps for the user**:
1.  **Re-clustering and doublet removal**: The user should perform a rigorous re-clustering analysis, potentially using more stringent parameters, and apply robust doublet detection and removal algorithms. The presence of CD14 and MYL2 in significant fractions of cells strongly suggests contamination that needs to be addressed before a definitive annotation can be made.
2.  **Expression of missing markers**: It is critical to obtain expression data for the missing canonical markers: ACTA2, DES (for muscle contamination), CD68, FCGR3A (for macrophage contamination), and crucially, CD19, MS4A1 (CD20) (to definitively rule out B cell contamination and further confirm plasmablast identity).
3.  **Subpopulation analysis**: If the contamination issues are resolved, further sub-clustering might be warranted to investigate the heterogeneity within the plasmablast population, especially concerning the different immunoglobulin isotypes and the unusual CDKN1A expression.
